Microba Life Sciences (ASX:MAP) said new data showed the ability of its MetaPanel test to identify clinically significant pathogens missed by standard diagnostic approaches, according to a Wednesday Australian bourse filing.
The test is a gastrointestinal pathogen detection panel that screens for 115 pathogens and virulence factors, including bacteria, viruses, and parasites.
Analysis of 889 MetaPanel tests from a patient cohort characterized by long-term gastrointestinal symptoms showed 20% of patients tested positive for a pathogen that can cause gastrointestinal infection. Meanwhile, 58.3% of tests reveal abnormal microbiome results, supporting referral to a MetaXplore test for further investigation.
Around 78.4% of the pathogens detected by the MetaPanel test are often missed by routine pathology tests, per the filing.
Its shares fell 3% on market close Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.